Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe phrase 'stomach botox injections for weight loss' circulates on social media as though it describes an established treatment. It does not. Botulinum toxin injected endoscopically into the stomach muscle has been studied as an experimental obesity intervention, but it is not licensed for weight loss in the UK, is not available through the NHS for this purpose, and the evidence for it is weak at best. What is licensed, clinically studied, and available through a regulated UK pharmacy is a different class of injection entirely: GLP-1 and dual-agonist medicines such as Wegovy and Mounjaro, which are prescription-only medicines requiring a clinical assessment before a qualified prescriber can approve them. If you searched for stomach botox and arrived here hoping to understand your real options, read on.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Search algorithms have blended two very different ideas into a single phrase. 'Botox' (botulinum toxin) is licensed in the UK for specific cosmetic and medical uses, none of which include weight management. The experimental procedure sometimes called 'gastric botox' or 'intragastric botulinum toxin injection' involves delivering the toxin endoscopically into the stomach wall to temporarily weaken muscle contractions, theoretically slowing gastric emptying and reducing appetite. Small studies have explored this. The outcomes have been underwhelming: a systematic review of available trials found modest and inconsistent weight loss, nowhere near the effect sizes of licensed medicines, with effects wearing off within months as the toxin degrades.
More importantly, no regulatory body (not the MHRA, not NICE) has licensed or recommended botulinum toxin for weight loss. Any clinic offering it in the UK is doing so on an entirely off-label basis, outside established clinical guidelines. That is a very different risk profile from a medicine that has completed phase-3 trials, received MHRA marketing authorisation, and is subject to ongoing pharmacovigilance. The NHS overview of obesity treatment does not list intragastric botox among recommended options — because it isn't one.
The confusion is understandable. 'Injection for weight loss' is a genuinely meaningful phrase in 2025 and 2026, because a new generation of injectable medicines has transformed what medical weight management can do. But that story belongs to a completely different drug class.
Wegovy (semaglutide) and Mounjaro (tirzepatide) are once-weekly subcutaneous injections administered just under the skin of the abdomen, thigh or upper arm, not into the stomach cavity. They do not paralyse muscle. They work by mimicking gut hormones that regulate appetite, satiety and blood-sugar control. Semaglutide activates the GLP-1 receptor; tirzepatide activates both GLP-1 and GIP receptors, making it the only dual-agonist weight-loss medicine licensed in the UK.
The evidence base is large and peer-reviewed. In SURMOUNT-1, participants taking tirzepatide at the highest dose lost an average of around 20–21% of body weight over 72 weeks, as published in the New England Journal of Medicine. The STEP 1 trial for semaglutide 2.4mg showed around 15% average weight reduction over 68 weeks. Both figures come from thousands of participants, not the small, mixed samples that gastric botox research has relied on. NICE reviewed this evidence for tirzepatide and issued a positive recommendation in December 2024 (TA1026).
These are prescription-only medicines for a reason. They have a well-characterised side-effect profile, require individual clinical assessment, and are titrated gradually under prescriber supervision. You can read about how stomach injections for weight loss are administered if you want a practical sense of what the self-injection process involves.
Both Wegovy and Mounjaro are licensed for adults with a BMI of 30 or above, or a BMI of 27 or above where at least one weight-related condition is present, for example, high blood pressure, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The prescriber looks at the whole picture, not just the number on the scale, and BMI alone does not guarantee approval.
NHS access exists but is phased and restricted: tirzepatide through primary care currently requires a BMI of 40 or above with multiple qualifying conditions, and Wegovy through specialist services typically involves a waiting list. Many people look at the cost of private weight-loss injections and weigh that against an uncertain wait, that is a very personal calculation.
Through a regulated private pharmacy, the route is a formal clinical consultation, identity and weight verification, and a same-day review by a GPhC-registered prescriber before anything is prescribed. A real clinician reads your answers, not software, not a checklist with an auto-approve at the end. If approved before midday on a working day, your treatment is dispatched that afternoon and arrives the next working day, tracked, in plain packaging. Before your first injection, it is worth knowing about the side effects associated with stomach injection sites and what to watch for.
This matters beyond academic licensing technicalities. The MHRA has seized approximately 20 million doses of illegally traded weight-loss medicines (worth an estimated £45 million) and raided the UK's first illicit manufacturing site producing counterfeit tirzepatide pens. Fake pens have contained insulin, causing hospitalisations. If a product is being sold online, through social media, or by a provider who cannot demonstrate a licensed supply chain and a GPhC-registered pharmacy behind it, the contents are unknown.
That applies equally to botulinum toxin products and to anything labelled as Mounjaro or Wegovy sold without a valid prescription. The safe route is a pharmacy you can verify on the GPhC register, a search by premises number takes about thirty seconds and tells you immediately whether a provider is regulated. Suspect medicines and suspect sellers can be reported at yellowcard.mhra.gov.uk. Worth checking before you commit to anything.
If you are looking at injectable weight-loss treatments and want to understand what is genuinely available and clinically appropriate for your situation, a free consultation is the right starting point. There is no pressure and no obligation, a prescriber simply looks at your health picture and tells you honestly whether treatment is suitable. Patients in the south-east can find out more about accessing weight loss injections in Guildford, while those in north-west London can explore weight loss injections available in Harrow. Check your eligibility and start your free consultation here.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.